Testing BL-M07D1 for HER2-positive or low solid tumors
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary clinical trials.
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor that tests positive or low for HER2 (a protein on some cancer cells).
- You are between 18 and 75 years old.
- You can still take care of yourself and are up and about (ECOG 0 or 1).
- You have not had certain types of chemotherapy or antibody-drug conjugates recently.
- You have not had other cancers in the last 5 years, and your heart and organ function are relatively healthy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
This trial tests a new drug called BL-M08D for people with advanced digestive tract tumors or other solid tumors that have spread. It aims to see if the drug can shrink tumors and improve survival, while monitoring safety.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial compares a new drug, BL-M07D1, to an existing treatment (DS-8201) for women with HR-positive, HER2-low breast cancer that has come back or spread. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
Hear when a new Her2-positive/Low-expression Urinary and Digestive Tract Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.